Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in July 2019 on request of the sponsor.
On 21 October 2004, orphan designation (EU/3/04/229) was granted by the European Commission to BioAlliance Pharma, France, for doxorubicin polyisohexylcyanoacrylate nanoparticles for the treatment of hepatocellular carcinoma.
In October 2014, BioAlliance Pharma changed name to Onxeo.
For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.
Doxorubicine polyisohexylcyanoacrylate nanoparticles
|Disease / condition||
Treatment of hepatocellular carcinoma
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;